KANDY THERAPEUTICS

Forbion Portfolio Company, KaNDy Therapeutics, to Be Acquired by Bayer

Retrieved on:

Tuesday, August 11, 2020

We are delighted that Bayer has decided to acquire KaNDy and support the ongoing work around the symptoms of menopause.

Key Points:

We are delighted that Bayer has decided to acquire KaNDy and support the ongoing work around the symptoms of menopause.
Bayer has been our preferred partner due to its leading position in the area of womens healthcare, said Dr. Mary Kerr, Co-Founder and CEO of KaNDy Therapeutics.
Goldman Sachs International is serving as financial advisor to KaNDy Therapeutics Ltd., while Goodwin is serving as legal counsel.
Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world.

Retrieved on:

Monday, January 13, 2020

The SWITCH-1 study was a randomised, double-blind, placebo-controlled trial conducted in the US, UK and Canada.

Key Points:

The SWITCH-1 study was a randomised, double-blind, placebo-controlled trial conducted in the US, UK and Canada.
NT-814 was well tolerated across the dose range with a safety profile that supports progression to Phase 3.
Dr Mary Kerr, Co-Founder and CEO KaNDy Therapeutics, said:
The SWITCH-1 study started in November 2018, and so we are excited to share such positive results on schedule.
The Company looks forward to presenting these data at future scientific meetings and discussing it with regulatory agencies in advance of progressing the compound into pivotal registration studies.

Retrieved on:

Monday, January 13, 2020

The SWITCH-1 study was a randomised, double-blind, placebo-controlled trial conducted in the US, UK and Canada.

Key Points:

The SWITCH-1 study was a randomised, double-blind, placebo-controlled trial conducted in the US, UK and Canada.
NT-814 was well tolerated across the dose range with a safety profile that supports progression to Phase 3.
Dr Mary Kerr, Co-Founder and CEO KaNDy Therapeutics, said:
The SWITCH-1 study started in November 2018, and so we are excited to share such positive results on schedule.
The Company looks forward to presenting these data at future scientific meetings and discussing it with regulatory agencies in advance of progressing the compound into pivotal registration studies.